Literature DB >> 17476687

Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.

Lisa G Horvath1, Jayne E Lelliott, James G Kench, C-Soon Lee, Elizabeth D Williams, Darren N Saunders, John J Grygiel, Robert L Sutherland, Susan M Henshall.   

Abstract

BACKGROUND: Secreted frizzled-related proteins (sFRP4) inhibits Wnt signaling and thus cellular proliferation in androgen-independent prostate cancer cells in vitro. However, increased expression of membranous sFRP4 is associated with a good prognosis in human localized androgen-dependent prostate cancer, suggesting a role for sFRP4 in early stage disease. Here, we investigated the phenotype of sFRP4 overexpression in an androgen-dependent prostate cancer model.
METHODS: An sFRP4-overexpressing androgen-dependent (LNCaP) prostate cancer model was established to assess changes in cellular proliferation, the expression, and subcellular localization of adhesion molecules and cellular invasiveness, and compared with the findings in sFRP4-overexpressing androgen-independent cells (PC3).
RESULTS: sFRP4 overexpression in both cell line models resulted in a morphologic change to a more epithelioid cell type with increased localization of beta-catenin and cadherins (E-cadherin in LNCaP, N-cadherin in PC3) to the cell membrane. Functionally, sFRP4 overexpression was associated with a decreased rate of proliferation (P = 0.0005), decreased anchorage-independent growth (P < 0.001), and decreased invasiveness in PC3 cells (P < 0.0001). Furthermore, increased membranous sFRP4 expression was associated with increased membranous beta-catenin expression (P = 0.02) in a cohort of 224 localized human androgen-dependent prostate cancers.
CONCLUSIONS: These data suggest that sFRP4 is an inhibitor of prostate cancer growth and invasion in vitro independent of androgen receptor (AR) signaling with correlative evidence in human androgen-dependent disease suggesting similar changes in the clinical setting. Consequently, potential therapeutic strategies to modulate Wnt signaling by sFRP4 will be relevant to both localized androgen-dependent prostate cancer and advanced metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17476687     DOI: 10.1002/pros.20607

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Catch-up growth after hypothyroidism is caused by delayed growth plate senescence.

Authors:  Rose Marino; Anita Hegde; Kevin M Barnes; Lenneke Schrier; Joyce A Emons; Ola Nilsson; Jeffrey Baron
Journal:  Endocrinology       Date:  2008-01-03       Impact factor: 4.736

2.  Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Authors:  Hua Jiang; Qingqing Li; Chengzhi He; Fengru Li; Haihui Sheng; Xiaoying Shen; Xiaoyan Zhang; Shizhang Zhu; Hui Chen; Ximei Chen; Changqing Yang; Hengjun Gao
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 3.  Wnt/β-catenin signalling in prostate cancer.

Authors:  Robert M Kypta; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

Review 4.  Secreted frizzled-related protein 4 and its implications in cancer and apoptosis.

Authors:  Sebastian Pohl; Ross Scott; Frank Arfuso; Vanathi Perumal; Arun Dharmarajan
Journal:  Tumour Biol       Date:  2014-12-13

5.  Enhanced estrogen-induced proliferation in obese rat endometrium.

Authors:  Qian Zhang; Qi Shen; Joseph Celestino; Michael R Milam; Shannon N Westin; Robin A Lacour; Larissa A Meyer; Gregory L Shipley; Peter J A Davies; Lei Deng; Adrienne S McCampbell; Russell R Broaddus; Karen H Lu
Journal:  Am J Obstet Gynecol       Date:  2009-02       Impact factor: 8.661

6.  Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.

Authors:  Antoinette S Perry; Gillian O'Hurley; Omer A Raheem; Kevin Brennan; Simon Wong; Anthony O'Grady; Anne-Marie Kennedy; Laure Marignol; Therese M Murphy; Linda Sullivan; Ciara Barrett; Barbara Loftus; John Thornhill; Stephen M Hewitt; Mark Lawler; Elaine Kay; Thomas Lynch; Donal Hollywood
Journal:  Int J Cancer       Date:  2012-09-28       Impact factor: 7.396

7.  Involvement of tazarotene-induced gene 1 in proliferation and differentiation of human adipose tissue-derived mesenchymal stem cells.

Authors:  S Ohnishi; K Okabe; H Obata; K Otani; S Ishikane; H Ogino; S Kitamura; N Nagaya
Journal:  Cell Prolif       Date:  2009-02-24       Impact factor: 6.831

Review 8.  Targeting Wnt Signaling in Endometrial Cancer.

Authors:  Iram Fatima; Susmita Barman; Rajani Rai; Kristina W W Thiel; Vishal Chandra
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

9.  Screening of differentially expressed genes in the growth plate of broiler chickens with tibial dyschondroplasia by microarray analysis.

Authors:  Wen-xia Tian; Jia-kui Li; Ping Qin; Rui Wang; Guan-bao Ning; Jian-gang Qiao; Hong-quan Li; Ding-ren Bi; Si-yi Pan; Ding-zong Guo
Journal:  BMC Genomics       Date:  2013-04-23       Impact factor: 3.969

10.  The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Authors:  Caroline E Ford; Eve Jary; Sean Si Qian Ma; Sheri Nixdorf; Viola A Heinzelmann-Schwarz; Robyn L Ward
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.